Product
LVRNA009
3 clinical trials
1 indication
Indication
COVID-19Clinical trial
A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19 in Participants Aged 18 Years and OlderStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) in Chinese People Aged 18 Years and OverStatus: Active (not recruiting), Estimated PCD: 2022-10-14
Clinical trial
A Randomized, Blinded, Parallel-controlled Phase 3 Study to Evaluate the Immunogenicity and Safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as Heterologous Booster in Participants Aged 18 Years and Older Vaccinated 2 Doses Inactivated SARS-CoV-2 VaccineStatus: Not yet recruiting, Estimated PCD: 2023-10-01